Neutropenia < 2.0 x 109/L 80 82 < 0.5 x 109/L 9 22 Thrombocytopenia < 100 x 109/L 2 3 < 50 x 109/L <1 <1 Anaemia < 110 g/L 33 25 < 80 g/L 1 <1 Infections 24 20 Neutropenic sepsis <1 <1 Febrile Neutropenia 2 1 Bleeding 2 2 Hypersensitivity Reactione All 4 12 Severef 0 2 Cardiovascular Sign Changesg Bradycardia <1 <1 Hypotension 5 5 Severe Cardiovascular 3 4 Eventsf Abnormal ECG All patients 60 52 Patients with Normal 35 30 Baseline Respiratory Cough 7 6 Dyspnea 12 9 Peripheral Neuropathy Any Symptoms 71 56 Severe Symptomsf 10 2 Table 7: Frequencya of Important Treatment Emergent Adverse Effects in Metastatic Breast Cancer in the Randomised Study on an Every-3-Weeks Schedule, Continued Percent of Patients ABRAXANE Solvent-based paclitaxel 260/30minb 175/3hc,d (n=229) (n=225) Myalgia / Arthralgia Any Symptoms 44 49 Severe Symptomsf 8 4 Asthenia Any Symptoms 47 39 Severe Symptomsf 8 3 Fluid Retention / Oedema Any Symptoms 10 8 Severe Symptomsf 0 <1 Gastrointestinal Nausea Any Symptoms 30 22
Neutropenia < 2.0 x 109/L < 0.5 x 109/L 80 9 82 22 Thrombocytopenia < 100 x 109/L < 50 x 109/L 2 <1 3 <1 Anaemia < 110 g/L < 80 g/L 33 1 25 <1 Infections 24 20 Neutropenic sepsis <1 <1 Febrile Neutropenia 2 1 Bleeding 2 2 Hypersensitivity Reactione All 4 12 Severef 0 2 Cardiovascular Sign Changesg Bradycardia <1 <1 Hypotension 5 5 Severe Cardiovascular Eventsf 3 4 Abnormal ECG All patients 60 52 Patients with Normal Baseline 35 30 Respiratory Cough 7 6 Dyspnea 12 9 Peripheral Neuropathy Any Symptoms 71 56 Severe Symptomsf 10 2 Table 7: Frequencya of Important Treatment Emergent Adverse Effects in Metastatic Breast Cancer in the Randomised Study on an Every-3-Weeks Schedule, Continued Percent of Patients ABRAXANE 260/30minb (n=229) Solvent-based paclitaxel 175/3hc,d (n=225) Myalgia / Arthralgia Any Symptoms 44 49 Severe Symptomsf 8 4 Asthenia Any Symptoms 47 39 Severe Symptomsf 8 3 Fluid Retention / Oedema Any Symptoms 10 8 Severe Symptomsf 0 <1 Gastrointestinal Nausea Any Symptoms 30 22
auspar-nab-paclitaxel-140617-pi.docx